系统性红斑狼中的阿尼弗罗卢马布:来自单一学术三级护理中心的现实世界经验
Paul Classen1, Simone Boedecker-Lips1, Vanessa Tomalla1
1Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Clinical and experimental rheumatology
|September 26, 2025
概括
阿尼弗罗卢马布有效地降低了全身性红斑狼 (SLE) 疾病的活性,并在现实环境中实现了缓解. 这种I型干扰素受体抗剂在SLE患者中证明了安全性和耐受性.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性红斑狼 (SLE) 是一种慢性自身免疫性疾病,其特征是广泛的炎症.
- I型干扰素在SLE的发病过程中起着至关重要的作用.
- 阿尼弗罗卢马布向I型干扰素受体子单元1,提供了一种新的治疗方法.
研究的目的:
- 评估anifrolumab在SLE患者中的实际有效性和安全性.
- 评估阿尼弗罗卢马布治疗期间的疾病活性,临床过程和不良事件.
- 为了确定阿尼弗罗卢马布对缓解和低疾病活性状态的影响.
主要方法:
- 在德国一所学术高等保健中心对26名SLE患者进行前性观察队列研究.
- 根据当前欧洲反风湿联盟 (EULAR) 的指导方针开始治疗.
- 在多个时间点监测到24个月的疾病活动,临床过程和不良事件.
主要成果:
- 在3个月内,SLE疾病活动指数2000 (SLEDAI-2k) 和欧洲共识狼活动测量 (ECLAM) 的得分显著降低.
- 在12个月内实现了高缓解率 (DORIS:53%) 和狼低疾病活性状态 (LLDAS:89%).
- 粘膜皮肤表现,疲劳和关节炎/关节痛的快速改善;降低葡萄糖皮质激素剂量;良好的安全性.
结论:
- 在现实环境中,阿尼弗罗卢马布在减少SLE疾病活动和实现缓解方面表现出持续的有效性.
- 无论先前的治疗方法或疾病持续时间如何,都观察到治疗效益.
- 对于活跃的SLE患者来说,阿尼弗罗卢马布是一种安全且耐受良好的选择.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
437
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
437
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:21Rheumatic Heart Disease III: Medical Management
289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289
01:29Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460